翰思艾泰重塑CD47赛道引领肿瘤免疫治疗迈入黄金时代

泡财经01-13

当前，PD-(L)1抑制剂行业正处于发展转折点。翰思艾泰（3378.HK）以颠覆性创新打破困局，凭借两款重磅管线HX009、HX044的突破性进展，让CD47强势崛起，正式开启肿瘤免疫治疗的全新篇章。作为CD47新机制的开拓者与领航者，翰思艾泰跳出传统“别吃我”信号阻断的单一框架，深度解码CD47在肿瘤免疫中的核心调控密码。最新顶尖研究证实，CD47不仅是固有免疫的抑制信号，更是驱动T细胞耗竭、...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2603165921?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-13 18:35","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2603165921","market":"hk","top_or_hot":-1,"title":"翰思艾泰重塑CD47赛道 引领肿瘤免疫治疗迈入黄金时代","media":"泡财经","content":"<div>\n<p>当前，PD-(L)1抑制剂行业正处于发展转折点。翰思艾泰（3378.HK）以颠覆性创新打破困局，凭借两款重磅管线HX009、HX044的突破性进展，让CD47强势崛起，正式开启肿瘤免疫治疗的全新篇章。作为CD47新机制的开拓者与领航者，翰思艾泰跳出传统“别吃我”信号阻断的单一框架，深度解码CD47在肿瘤免疫中的核心调控密码。最新顶尖研究证实，CD47不仅是固有免疫的抑制信号，更是驱动T细胞耗竭、...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113190019a7158885&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>翰思艾泰重塑CD47赛道 引领肿瘤免疫治疗迈入黄金时代</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n翰思艾泰重塑CD47赛道 引领肿瘤免疫治疗迈入黄金时代\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-13 18:35 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113190019a7158885&s=b><strong>泡财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>当前，PD-(L)1抑制剂行业正处于发展转折点。翰思艾泰（3378.HK）以颠覆性创新打破困局，凭借两款重磅管线HX009、HX044的突破性进展，让CD47强势崛起，正式开启肿瘤免疫治疗的全新篇章。作为CD47新机制的开拓者与领航者，翰思艾泰跳出传统“别吃我”信号阻断的单一框架，深度解码CD47在肿瘤免疫中的核心调控密码。最新顶尖研究证实，CD47不仅是固有免疫的抑制信号，更是驱动T细胞耗竭、...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113190019a7158885&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1535","symbol_name":"港口运输股","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113190019a7158885&s=b","article_id":"2603165921","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113190019a7158885&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603165921","pubTimestamp":1768300517,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"翰思艾泰以颠覆性创新打破困局，凭借两款重磅管线HX009、HX044的突破性进展，让CD47强势崛起，正式开启肿瘤免疫治疗的全新篇章。作为CD47新机制的开拓者与领航者，翰思艾泰跳出传统“别吃我”信号阻断的单一框架，深度解码CD47在肿瘤免疫中的核心调控密码。两款重磅管线不仅有效攻克了传统CD47疗法的毒性痛点，更开辟了免疫检查点联合靶向的全新治疗路径。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1535":"港口运输股","BK1173":"海港与服务","03378":"翰思艾泰-B"},"translate_title":"Hans Aitai reshapes the CD47 track and leads tumor immunotherapy into the golden age","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1.5},"content_text":"当前，PD-(L)1抑制剂行业正处于发展转折点。翰思艾泰（3378.HK）以颠覆性创新打破困局，凭借两款重磅管线HX009、HX044的突破性进展，让CD47强势崛起，正式开启肿瘤免疫治疗的全新篇章。作为CD47新机制的开拓者与领航者，翰思艾泰跳出传统“别吃我”信号阻断的单一框架，深度解码CD47在肿瘤免疫中的核心调控密码。最新顶尖研究证实，CD47不仅是固有免疫的抑制信号，更是驱动T细胞耗竭、激活肿瘤调节T细胞（Treg）的关键适应性免疫检查点——其高表达与免疫治疗耐药直接相关，这一重大发现为靶向药物研发点亮了全新航向，而翰思艾泰早已精准布局，抢占技术制高点。公司产品HX009，是一种同时靶向CD47及PD-1的双特异性抗体融合蛋白，实现了行业两大历史性突破：一方面通过cis-binding独特机制，同步阻断T细胞上的PD-1和CD47信号，强效重激活耗竭T细胞，抗肿瘤活性远超传统疗法；另一方面， 肿瘤细胞表达的CD47可透过与巨噬细胞上的SIRPα相互作用，抑制其吞噬功能；而 PD-1则会抑制T细胞介导的肿瘤杀伤作用。临床数据方面，10mg/kg剂量下安全性表现卓越，无严重血液毒性困扰，更在PD-1经治的难治性患者中观察到明确临床活性。目前，HX009已顺利完成I期临床，正全速推进晚期黑色素瘤、EBV阳性非霍奇金淋巴瘤、晚期胆道癌等多个II期研究，更成功获批与Enhertu联合治疗晚期三阴性乳腺癌，多癌种、多联合方案的布局，彰显其无可限量的应用潜力！另一款全球首创管线HX044，聚焦CTLA-4与CD47双靶点，以独创的单臂1+1分子设计，主动优化双靶点亲和力，通过共表达双价结合技术，精准锁定肿瘤内Treg细胞。这一革命性设计实现了“精准打击+安全护航”的双重飞跃：既能通过ADCC效应特异性清除肿瘤内免疫抑制性Treg，释放免疫系统抗肿瘤潜能，又不损伤外周正常Treg及红细胞，安全窗口大幅拓宽。作为全球首个进入临床阶段的CTLA-4/CD47双抗，HX044已同步在中澳启动临床试验入组，并成功获批与PD-1联用治疗晚期实体瘤，有望改写实体瘤免疫治疗的竞争格局，为患者带来全新生机。业内人士指出，在CD47赛道从沉寂到爆发的历史性跨越中，翰思艾泰以前瞻性的机制探索、颠覆性的分子设计、扎实亮眼的临床数据，构建起不可复制的核心竞争优势。两款重磅管线不仅有效攻克了传统CD47疗法的毒性痛点，更开辟了免疫检查点联合靶向的全新治疗路径。翰思艾泰表示，未来，公司将持续深耕CD47新机制，加速推进更多创新药物的临床转化，以强大的管线价值赋能行业发展，用顶尖科学力量攻克肿瘤治疗难关，书写免疫治疗的全新传奇。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603165921","isCrawlerRequest":true}

翰思艾泰重塑CD47赛道 引领肿瘤免疫治疗迈入黄金时代

精彩评论

翰思艾泰重塑CD47赛道引领肿瘤免疫治疗迈入黄金时代